ETOFIBRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H18ClNO5
Molecular Weight	363.792
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C2=CN=CC=C2

InChI

InChIKey=XXRVYAFBUDSLJX-UHFFFAOYSA-N

InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3

HIDE SMILES / InChI

Description
Sources: https://hanwhapm.en.ec21.com/Lipo-Merz-retard-cap.--551243_551266.html | https://medikamio.com/de-de/medikamente/lipo-merz-retard/pil | http://www.google.com/patents/WO2003088962A1

Etofibrate is an ethylene glycol diester of clofibrate and nicotinic acid. The drug was used under the names Tricerol and Lipo-Merz, among the others, for the treatment of severe hypertriglyceridemia and mixed hyperlipidemia. The mechanism of etofibrate action implies activation of PPAR-alpha receptors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62 Target ID: Q07869 Gene ID: 5465.0 Gene Symbol: PPARA Target Organism: Homo sapiens (Human) Sources: http://www.google.com/patents/WO2003088962A1	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Severe hypertriglyceridemia 1 Sources: https://hanwhapm.en.ec21.com/Lipo-Merz-retard-cap.--551243_551266.html https://medikamio.com/de-de/medikamente/lipo-merz-retard/pil	Primary		Approved 8583	LIPO-MERZ RETARD Approved Use Lipo-Merz retard is indicated as an adjuvant treatment for a diet or other non-drug therapies (eg exercise, weight loss) for the following diseases: (1) severe hypertriglyceridemia; (2) mixed hyperlipidemia.
Mixed hyperlipidemia 2 Sources: https://hanwhapm.en.ec21.com/Lipo-Merz-retard-cap.--551243_551266.html https://medikamio.com/de-de/medikamente/lipo-merz-retard/pil	Primary		Approved 8583	LIPO-MERZ RETARD Approved Use Lipo-Merz retard is indicated as an adjuvant treatment for a diet or other non-drug therapies (eg exercise, weight loss) for the following diseases: (1) severe hypertriglyceridemia; (2) mixed hyperlipidemia.

PubMed

Title	Date	PubMed
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.	2010-11	21139869
Methods of chromatographic determination of medicines decreasing the level of cholesterol.	2010-09-30	20873411
[Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].	2009-07	19644802
Etofibrate enhances 123I-LDL-binding in human liver.	2009-02-07	19330175
Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques.	2008-11-05	18980118
Substituted tertiary phosphine Ru(II) organometallics: catalytic utility on the hydrolysis of etofibrate in pharmaceuticals.	2008-10	18160337
Peroxisome proliferator activated receptors and lipoprotein metabolism.	2008	18288277
High performance liquid chromatographic determination of etofibrate and its hydrolysis products.	2007-01-04	16901673
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.	2006	17722529
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.	2003-09	14520596
Mass spectrometric monitoring of the degradation and elimination efficiency for hardly eliminable and hardly biodegradable polar compounds by membrane bioreactors.	2002	12227604
Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.	2001-02-01	11166779
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.	2001-02	11175492
Treatment of dyslipoproteinemia in the metabolic syndrome.	2001	11453042
Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.	1988-11-04	3179329
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.	1985	4072624

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 1 sustained-release capsule (500 mg) once daily. In special cases, up to 2 sustained-release capsules can be prescribed.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

ETOFIBRATE

Official Name

English

ETOFIBRATE [MI]

Preferred Name

English

ETOFIBRATE [MART.]

Common Name

English

Etofibrate [WHO-DD]

Common Name

English

2-HYDROXYETHYL NICOTINATE 2-(P-CHLOROPHENOXY)-2-METHYLPROPIONATE (ESTER)

Common Name

English

etofibrate [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC10AB09